ChemWerth appoints Dr. Jeffrey Bauer as President

ChemWerth, Inc., has appointed Dr. Jeffrey Bauer as President effective. Dr. Bauer takes on the responsibility for leading the day-to-day business operations of ChemWerth, as well as charting its future growth strategy. Prior to joining ChemWerth, Dr. Bauer held the position of Vice President, Business Development and Licensing at Sandoz, Inc. (Princeton, NJ), a position that he held for five years beginning in 2005. At Sandoz, Dr. Bauer had broad responsibilities including management of the United States generic product portfolio as well as active pharmaceutical ingredient (API) sourcing and procurement. Prior to joining Sandoz, Dr. Bauer was employed at Eon Labs, Inc., another generic pharmaceutical company that was acquired by Sandoz in July 2005. During his five year tenure at Eon Labs, he served as Vice President of Business Development and Licensing with similar responsibilities and duties as those he held at Sandoz. Dr. Bauer’s previous experience included positions at Ivax Pharmaceuticals, AAIPharma and Bio-Rad Laboratories in which he served in various capacities including: regulatory affairs, project management, portfolio management and API sourcing. In all, he brings 18 years of professional experience in the pharmaceutical and medical device industries. Dr. Bauer earned a Bachelor of Science in Biology from Tufts University in Boston, a Master of Science in Toxicology from Duquesne University and his Ph.D. in Pharmacology from the University of North Carolina at Chapel Hill.